keyword
MENU ▼
Read by QxMD icon Read
search

conbercept

keyword
https://www.readbyqxmd.com/read/29549425/the-efficacy-of-conbercept-or-ranibizumab-intravitreal-injection-combined-with-laser-therapy-for-coats-disease
#1
Longli Zhang, Yifeng Ke, Wei Wang, Xueying Shi, Kaiwen Hei, Xiaorong Li
PURPOSE: The current treatment approaches for Coats' disease by intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents (ranibizumab or conbercept) combined with laser therapy were evaluated for the efficacy during the treatment. METHODS: The medical records of 28 patients diagnosed with Coats' disease followed by the treatment with intravitreal injection of anti-VEGF agents and laser therapies at Tianjin Medical University Eye Hospital and Hebei Eye Hospital during July 2012 and October 2017 were reviewed retrospectively...
March 16, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29547454/conbercept-in-patients-with-treatment-naive-neovascular-age-related-macular-degeneration-in-real-life-setting-in-china
#2
Xun Li, Hongmei Luo, Cheng Zuo, Zirong Zhang, Junjun Zhang, Meixia Zhang
PURPOSE: In this study, we aimed to evaluate the efficacy and safety of intravitreal conbercept in patients with treatment-naive neovascular age-related macular degeneration in real-life setting. METHODS: Three consecutive intravitreal injections of conbercept following a pro re nata protocol. The main outcomes were the changes of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity and central retinal thickness between the baseline and the 12th month...
March 15, 2018: Retina
https://www.readbyqxmd.com/read/29507304/observation-of-optic-disc-neovascularization-using-oct-angiography-in-proliferative-diabetic-retinopathy-after-intravitreal-conbercept-injections
#3
Xiao Zhang, Chan Wu, Li-Jia Zhou, Rong-Ping Dai
This study reports the short-term efficacy and safety of intravitreal conbercept injections for neovascularization at the disc (NVD) in patients with proliferative diabetic retinopathy (PDR). Conbercept is a recombinant fusion protein with a high affinity for all isoforms of vascular endothelial growth factor (VEGF)-A, placental growth factor and VEGF-B. A prospective case series study was conducted in 15 patients (15 eyes). Patients had complete ocular examinations and received a 0.5 mg intravitreal conbercept injection followed by supplemental pan-retinal photocoagulation (PRP)...
March 5, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29497280/short-term-efficacy-of-intravitreal-conbercept-in-treatment-naive-patients-with-polypoidal-choroidal-vasculopathy
#4
Yuting Peng, Xiongze Zhang, Miaoling Li, Bing Liu, Lan Mi, Chengguo Zuo, Feng Wen
Introduction: To evaluate the functional and morphological outcomes of intravitreal conbercept monotherapy in patients with polypoidal choroidal vasculopathy (PCV). Materials and methods: In this retrospective, observational case series study, we reviewed medical records of 48 eyes (48 patients) with naive PCV that were treated with a series of 3 monthly intravitreal injections of 0.5 mg of conbercept followed by as-needed injections (3+pro re nata). All patients completed at least 6 months of monthly follow-up...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29382038/extended-duration-vascular-endothelial-growth-factor-inhibition-in-the-eye-failures-successes-and-future-possibilities
#5
REVIEW
Michael W Stewart
Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of neovascularization and edema from several common chorioretinal vascular conditions. The intravitreally injected drugs (aflibercept, bevacizumab, conbercept, pegaptanib, and ranibizumab) used to treat these conditions improve the visual acuity and macular morphology in most patients. Monthly or bimonthly injections were administered in the phase III pivotal trials but physicians usually individualize therapy with pro re nata (PRN) or treat and extend regimens...
January 27, 2018: Pharmaceutics
https://www.readbyqxmd.com/read/29360683/short-term-efficacy-of-conbercept-and-ranibizumab-for-polypoidal-choroidal-vasculopathy
#6
Zhen Huang, Qin Ding, Min Yan, Haiyan Lian, Zhongshan Chen, Xiao Chen, Yanping Song
PURPOSE: To compare the 6-month efficacy of the intravitreal injection of conbercept or ranibizumab for patients with polypoidal choroidal vasculopathy (PCV). METHODS: This is a retrospective case-control study involved 79 PCV eyes of 77 patients. The PCV eyes were treated with an intravitreal injection of either ranibizumab (n = 44) or conbercept (n = 35). Three monthly loading doses were injected and followed by retreatment as needed. The best-corrected visual acuity and angiographic characteristics were evaluated after 6 months...
January 19, 2018: Retina
https://www.readbyqxmd.com/read/29343949/clinical-observations-on-the-use-of-new-anti-vegf-drug-conbercept-in-age-related-macular-degeneration-therapy-a-meta-analysis
#7
Chunmei Cui, Hong Lu
Purpose: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of age-related macular degeneration (AMD). Although this novel drug has been widely used in clinic, unlike other anti-VEGF drugs, validation and consensus on its method of clinical application and clinical safety have not yet been achieved. Methods: Relevant literature was searched on PubMed, Web of Science, China National Knowledge Internet, and Wanfang Data...
2018: Clinical Interventions in Aging
https://www.readbyqxmd.com/read/29319204/observation-of-curative-effect-of-intravitreal-injection-of-conbercept-in-wet-age-related-macular-degeneration-optical-coherence-tomography-analysis-after-injection
#8
Wen Yang, Ying Tan, Chaowei Li, Yi Liu, Guohua Lu
To observe the clinical efficacy of intravitreal injection of conbercept in the treatment of wet age-related macular degeneration (wAMD), optical coherence tomography (OCT) and the best corrected visual acuity (BCVA) was observed to measure the changes of anatomical changes of central macular thickness (CMT) and the area and volume of retinal pigment epithelium (RPE) uplift. Fifteen patients (15 eyes) with wet AMD were enrolled in this study. All patients underwent intravitreal injection of conbercept of 0...
April 2018: Microscopy Research and Technique
https://www.readbyqxmd.com/read/29185839/therapeutic-efficacy-of-conbercept-for-inflammatory-choroidal-neovascularization
#9
Yutong Chen, Rui Hua
No abstract text is available yet for this article.
November 29, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28980574/-anti-vegf-therapy-resistance-in-neovascular-age-related-macular-degeneration
#10
M V Budzinskaya, A A Plyukhova, P A Sorokin
With account to the increase in the elderly population in most of the developed countries, the WHO defines age-related macular degeneration (AMD) as one of the main causes of blindness in the world. A large percentage of disability is accounted for by exudative, or neovascular, form of AMD. Today, a total of 5 anti-VEGF drugs exist that are recommended for treatment of exudative AMD: pegaptanib, ranibizumab, bevacizumab, aflibercept, and conbercept. Despite significant progress in the treatment of neovascular AMD yielded by the introduction into clinical practice of anti-VEGF drugs, some patients report a lack (down to complete lack) of response with standard treatment patterns and even a decrease in treatment efficacy after repeated intravitreal injections...
2017: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/28937147/comparison-of-effectiveness-and-safety-between-conbercept-and-ranibizumab-for-treatment-of-neovascular-age-related-macular-degeneration-a-retrospective-case-controlled-non-inferiority-multiple-center-study
#11
J Cui, D Sun, H Lu, R Dai, L Xing, H Dong, L Wang, D Wei, B Jiang, Y Jiao, M M Jablonski, S Charles, W Gu, H Chen
PurposeTo compare the efficacy and safety of conbercept and ranibizumab when administered according to a treat-and-extend (TREX) protocol for the treatment of neovascular age-related macular degeneration (AMD) in China.Patients and methodsBetween May 2014 and May 2015, 180 patients were treated in a 1 : 1 ratio using conbercept or ranibizumab from four hospitals. Patients received either conbercept 0.5 mg or ranibizumab 0.5 mg intravitreal injections. Follow-up time was 1 year and treated based on a TREX approach...
February 2018: Eye
https://www.readbyqxmd.com/read/28841827/comparison-of-12-month-therapeutic-effect-of-conbercept-and-ranibizumab-for-diabetic-macular-edema-a-real-life-clinical-practice-study
#12
Yule Xu, Ao Rong, Wei Xu, Yunli Niu, Zhen Wang
BACKGROUND: To compare the efficacy of intravitreal conbercept and ranibizumab in the treatment of diabetic macular edema (DME) in a real-life clinical practice. METHODS: This was a retrospective study. Among 62 Chinese patients with DME, 32 patients (36 eyes) received intravitreal conbercept (IVC) injections and 30 patients (32 eyes) received intravitreal ranibizumab (IVR) injections, once a month for 3 months followed by as needed therapy. All participants had at least 12 months of follow-up...
August 25, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28730115/diabetic-macular-edema-in-proliferative-stage-treated-with-anti-vascular-endothelial-growth-factor-agent-and-triamcinolone-acetonide-by-laser-based-strategies
#13
Gang Qiao, Wan-Jiang Dong, Yan Dai, Zhen-Hua Jiang, Hai-Ke Guo
AIM: To appraise the effect of treatment for diabetic macular edema (DME) in proliferative stage with sufficient panrentinal photocoagulation (PRP) therapy and intravitreal injections (IV) Conbercept and posterior subtenon's triamcinolone acetonide (STTA) sequential therapy. METHODS: This prospective clinical randomized controlled trial of cross-over design was conducted in three phases. The participants included cases of DME in proliferative stage. They were divided into two groups and treated with PRP before enrollment...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28699927/short-term-outcomes-after-intravitreal-injections-of-conbercept-versus-ranibizumab-for-the-treatment-of-retinopathy-of-prematurity
#14
Enzhong Jin, Hong Yin, Xiaoxin Li, Mingwei Zhao
PURPOSE: Intravitreal injection of conbercept (IVC) is the latest applied treatment that could be used in retinopathy of prematurity (ROP) patients. The structural outcomes and recurrence of ROP among patients treated with IVC or intravitreal injection of ranibizumab (IVR) were compared. METHODS: A consecutive case series of ROP treated with IVC or IVR were retrospectively studied. The primary outcome was treatment success defined as regression of plus disease. The secondary outcomes were recurrence of plus, times of injection, and the final regression of disease...
July 7, 2017: Retina
https://www.readbyqxmd.com/read/28606070/efficacy-and-safety-of-conbercept-as-a-primary-treatment-for-choroidal-neovascularization-secondary-to-punctate-inner-choroidopathy
#15
Yuting Peng, Xiongze Zhang, Lan Mi, Bing Liu, Chengguo Zuo, Miaoling Li, Feng Wen
BACKGROUND: To evaluate the efficacy and safety of intravitreal conbercept (KH902) as the primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy. METHODS: This study was a retrospective, consecutive, observational case series. We reviewed medical records of 16 eyes (16 patients) with naive subfoveal or juxtafoveal choroidal neovascularization secondary to punctuate inner choroidopathy that were treated with intravitreal conbercept injections...
June 12, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28441077/comparison-of-conbercept-with-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-branch-retinal-vein-occlusion
#16
Fengjiao Li, Ming Sun, Jianlian Guo, Aihua Ma, Bojun Zhao
PURPOSE: To confirm the therapeutic efficacy of conbercept for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS: In this prospective, randomized, and comparative study, patients were randomized and divided into conbercept (n = 18) and ranibizumab (n = 17) groups. After an initial intravitreal injection of either conbercept or ranibizumab, a pro re nata (PRN) strategy was adopted based on loss of visual acuity (VA) or increase in central macular thickness (CMT)...
August 2017: Current Eye Research
https://www.readbyqxmd.com/read/28420611/characterization-of-the-conbercept-gene-localization-in-dhfr-amplified-cho-cells-using-fluorescence-in-situ-hybridization
#17
Ming-lei Shi, Wei-li Lai, Tian-hong Yi, Xiao Ke, Zhi-hu Zhao
Chinese-hamster ovary (CHO) cells are most widely used for mammalian protein expression. After integration into the CHO genome, the exogenous gene may be lost in the process of large-scale protein production due to the removal of related selection pressures. Therefore, it is necessary to test its stability in the genome. Conbercept is a fusion protein that specifically binds to the various isoforms of vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF), thereby exerting anti-angiogenic activities...
April 20, 2017: Yi Chuan, Hereditas
https://www.readbyqxmd.com/read/28377591/a-safety-study-of-high-concentration-and-high-frequency-intravitreal-injection-of-conbercept-in-rabbits
#18
Jiaming Wang, Chunyan Lei, Lifei Tao, Quan Wu, Xiao Ke, Yiguo Qiu, Bo Lei
The novel anti-VEGF drug conbercept has been used in the treatment of several retinal neovascular diseases. Owning to the alteration of the structure, the newest drug is capable of combining more molecular targets and present higher affinity to the angiogenesis promoting factors. However, it is unknown whether it will cause any unwanted effects like other anti-VEGF agents. We studied the short-term safety of high concentration and high frequency intravitreal injection of conbercept in rabbits. Intraocular pressure, fundus-photography, ERGs were applied...
April 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/27958226/correlation-of-vascular-endothelial-growth-factor-production-with-photochemical-reaction-induced-retinal-edema
#19
Liang Shan, Mi Zheng, Yuan Zhang, Yuan Qu, Tian Niu, Qing Gu, Kun Liu, Xin Xia
BACKGROUND: Retinal edema is the major complication of retinal vein occlusion and diabetic retinopathy; it can damage visual function by influencing macular region. This study was to establish a rat retinal edema model and explore the related VEGF expression and observe the responses to anti-VEGF drugs in this model. METHODS: A rat retinal edema model was established by inducing photochemical reaction using a 532 nm laser after the intravenous injection of Erythrosin B...
December 20, 2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27922068/changes-in-retinal-nerve-fiber-layer-thickness-after-multiple-injections-of-novel-vegf-decoy-receptor-conbercept-for-various-retinal-diseases
#20
Zhihua Zhang, Xiaolu Yang, Huiyi Jin, Yuan Qu, Yuan Zhang, Kun Liu, Xun Xu
Conbercept is a recombinant fusion protein with high affinity for all vascular endothelial growth factor isoforms and placental growth factor. The repeated intravitreal injection of conbercept may cause intraocular pressure (IOP) fluctuations and long-term suppression of neurotrophic cytokines, which could lead to retinal nerve fiber layer (RNFL) damage. This retrospective fellow-eye controlled study included 98 eyes of 49 patients. The changes in IOP and RNFL thickness as well as the correlation between RNFL changes and associated factors were evaluated...
December 6, 2016: Scientific Reports
keyword
keyword
81384
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"